Oxidative stress and mitochondrial dysfunction in type 2 diabetes

Current Pharmaceutical Design

Volumn 17, Issue 36, 2011, Pages 3947-3958

  Victor, Victor M ^a,b   Rocha, Milagros ^a   Herance, Raul ^c   Hernandez Mijares, Antonio ^a,b  

^a HOSPITAL UNIVERSITARIO DR PESET   (Spain)

^b UNIVERSITY OF VALENCIA   (Spain)

^c Barcelona Biomedical Research Park   (Spain)

Author keywords

Diabetes; Mitochondria; Oxidative stress; Reactive oxygen species

Indexed keywords

ACETYLCYSTEINE; ADENOSINE TRIPHOSPHATE; ALPHA TOCOPHEROL; ANTIOXIDANT; COPPER ZINC SUPEROXIDE DISMUTASE; EXTRACELLULAR SUPEROXIDE DISMUTASE; GLUCOSE; HEME OXYGENASE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; INSULIN; MANGANESE SUPEROXIDE DISMUTASE; MITOCHONDRIAL DNA; MITOFUSIN 1; NITRIC OXIDE; PROTEIN KINASE C; REACTIVE NITROGEN SPECIES; REACTIVE OXYGEN METABOLITE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE DEHYDROGENASE; SIRTUIN 1; UBIQUINONE; UNCOUPLING PROTEIN 1;

ANTIOXIDANT ACTIVITY; ARTICLE; AUTOPHAGY; BIOGENESIS; BLADDER CANCER; BREAST CANCER; CANCER RISK; CELL TRANSPORT; COLORECTAL CANCER; DIABETIC NEPHROPATHY; DISORDERS OF MITOCHONDRIAL FUNCTIONS; ENDOMETRIUM CANCER; ENDOPLASMIC RETICULUM; GENE OVEREXPRESSION; GLUCOSE BLOOD LEVEL; HUMAN; INFLAMMATION; INSULIN RELEASE; INSULIN RESISTANCE; INSULIN SENSITIVITY; INTRACELLULAR SIGNALING; KIDNEY CANCER; LIVER CANCER; MITOCHONDRIAL ENERGY TRANSFER; MITOCHONDRIAL RESPIRATION; MORPHOLOGY; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHODGKIN LYMPHOMA; NONHUMAN; OBESITY; OXIDATIVE PHOSPHORYLATION; OXIDATIVE STRESS; PANCREAS CANCER; PRIORITY JOURNAL; PROTEIN FOLDING; PROTEIN SYNTHESIS; PROTEIN TARGETING;

EID: 84855223468     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/138161211798764915     Document Type: Article

References (218)

1. Gutteridge JM, Mitchell J. Redox imbalance in critical ill. Br Med Bull 1999; 55: 49-75.
2. Gutteridge JM. Lipid peroxidation and antioxidants as biomarkers of tissue damage. Clin Chem 1995; 41: 1819-28.
3. Schachinger V, Britten MB, Zeiher AM. Prognostic impact of coronary vasodilator dysfunction on adverse long-term outcome of coronary heart disease. Circulation 2000; 101: 1899-906.
4. Kowaltowski, AJ, Vercesi AE. Mitochondrial damage induced by conditions of oxidative stress. Free Radic Biol Med 1999; 26: 463-71.
5. Victor VM, Rocha M, De la Fuente M. N-acetylcysteine protects mice from lethal endotoxemia by regulating the redox state of immune cells. Free Radic Res 2003; 37: 919-29.
6. Victor VM, Rocha, M, De la Fuente M. Immune cells: free radicals and antioxidants in sepsis. Int Immunopharmacol 2004; 4: 327-47.
7. Victor VM, Rocha M, Esplugues, JV, De la Fuente M. Role of free radicals in sepsis: antioxidant therapy. Curr Pharm Des 2005; 11: 3141-58.
8. Kagan, VE, Serbinova EA, Stoyanovsky DA, Khwaja S, Packer L. Assay of ubiquinones and ubiquinols as antioxidants. Methods En-zymol 1994; 234: 343-54.
9. Sheu SS, Nauduri D, Anders MW. Targeting antioxidants to mitochondria: a new therapeutic direction. Biochim Biophys Acta 2006; 1762: 256-65.
10. Victor VM, Rocha M. Targeting antioxidants to mitochondria: a potential new therapeutic strategy for cardiovascular diseases. Curr Pharm Des 2007; 13: 845-63.
11. Victor VM, Apostolova N, Herance R, Hernandez-Mijares A, Rocha M. Oxidative stress and mitochondrial dysfunction in athero sclerosis: mitochondria-targeted antioxidants as potential therapy. Curr Med Chem 2009; 16: 4654-67.
12. -), superoxide dismutases, and related matters. J Biol Chem 1997; 272: 18515-18517.
13. Erusalimsky JD, Moncada S. Nitric oxide and mitocondrial signaling: from physiology to pathophysiology. Arterioscler Thromb Vasc Biol 2007; 27: 2524-2531.
14. Huie RE, Padmaja S. The reaction of NO with superoxide. Free Radic Res Commun 1993; 18: 195-199.
15. Padmaja S, Huie RE. The reaction of nitric oxide with organic peroxyl radicals. Biochem Biophys Res Commun 1993; 195: 539-544.
16. Radi R, Rodriguez M, Castro L, Telleri R. Inhibition of mitochon-drial electron transport by peroxynitrite. Arch Biochem Biophys 1994; 308: 89-95.
17. Lacza Z, Pankotai E, Busija DW. Mitochondrial nitric oxide syn-thase: current concepts and controversies. Front Biosci 2009; 14: 4436-4443.
18. Boveris A, Cadenas E. cellular sources and steady-state levels of reactive oxygen species, in: LB Clerch, DJ Massaro (Eds), Oxygen, gene expression, and cellular function. New York: Marcel Dekker 1997; pp. 1-25.
19. Satarkov AA, Fiskum G, Chinopoulos C, et al. Mitochondrial a-ketoglutarate dehydrogenase complex generates reactive oxygen species. J Neurosci 2004; 24: 7779-88.
20. Rains JL, Jain SK. Oxidative stress, insulin signaling, and diabetes. Free Radic Biol Med 2011; 50:567-75.
21. Fialkow L, Wang Y, Downey GP. Reactive oxygen and nitrogen species as signaling molecules regulating neutrophil function. Free Radic Biol Med 2007; 42: 153-64.
22. Giacco F, Brownlee M. Oxidative stress and diabetic complications. Circ Res 2010; 107:1058-70.
23. Rocha M, Victor VM. Targeting antioxidants to mitochondria and cardiovascular diseases: the effects of mitoquinone. Med Sci Monit 2007; 13: 132-45.
24. Poderoso JJ, Carreras MC, Lisdero C, Riobó N, Schöpfer F, Bove-ris A. Nitric oxide inhibits electron transfer and increases superox-ide radical production in rat heart mitochondria and infmitochon-drial particles. Arch Biochem Biophys 1996; 328: 85-92.
25. White MY, Edwards AV, Cordwell, JJ, Van Eyk JE. Mitochondria: a mirror into cellular dysfunction in heart disease. Proteomics Clin Appl 2008; 2: 845-61.
26. Youle RJ, Narendra DP. Mechanisms of mitophagy. Nat Rev Mol Cell Biol 2011; 12: 9-14.
27. DiMauro, S.; Schon, E.A. Mitochondrial respiratory-chain diseases. N Engl J Med 2003, 348: 2656-68.
28. Rocha M, Hernandez-Mijares A, Garcia-Malpartida K, Bañuls C, Bellod L, Victor VM. Mitochondria-targeted antioxidant peptides. Curr Pharm Des 2010; 16: 3124-31.
29. Houstek J, Pickova A, Vojtiskova A, Mracek T, Pecina P, Jesina P. Mitochondrial diseases and genetic defects of ATP synthase. Bio-chim Biophys Acta 2006; 1757: 1400-5.
30. Brookes PS, Yoon Y, Robotham JL, Anders MW, Sheu SS. Calcium, ATP, and ROS: a mitochondrial love-hate triangle. Am J Physiol Cell Physiol 2004; 287: 817-33.
31. Indo HP, Davidson M, Yen HC, et al. Evidence of ROS generation by mitochondria in cells with impaired electron transport chain and mitochondrial DNA damage. Mitochondrion 2007; 7: 106-18.
32. Stavrovskaya, I.G, Kristal BS. The powerhouse takes control of the cell: is the mitochondrial permeability transition a viable therapeutic target against neuronal dysfunction and death? Free Radic Biol Med 2005; 38: 687-97.
33. Victor, VM, Rocha M, Bañuls C, et al. Mitochondrial complex I impairment in leukocytes from polycystic ovary syndrome patients with insulin resistance. J Clin Endocrinol Metab 2009; 94: 3505-12.
34. Hernandez-Mijares A, Rocha M, Apostolova N, et al. Mitochon-drial complex I impairment in leukocytes from type 2 diabetic patients. Free Radic Biol Med. 2011 Jan 22.
35. Esplugues JV, Rocha M, Nuñez C, et al. Complex I dysfunction and tolerance to nitroglycerin: an approach based on mitochondrial-targeted antioxidants. Circ Res 2006; 99: 1067-75.
36. Di Lisa, F.; Bernardi, P. Mitochondrial function and myocardial aging. A critical analysis of the role of permeability transition. Car-diovasc Res 2005, 66: 222-32.
37. Yakes FM, Van Houten B. Mitochondrial DNA damage is more extensive and persists longer than nuclear DNA damage in human cells following oxidative stress. Proc Natl Acad Sci USA 1997; 94: 514-9.
38. Wu YT, Wu SB, Lee WY, Wei YH. Mitochondrial respiratory dysfunction-elicited oxidative stress and posttranslational protein modification in mitochondrial diseases. Ann N Y Acad Sci 2010; 1201: 147-56.
39. Ramachandran A, Moellering DR, Ceaser E, Shiva S, Xu J, Darley-Usmar V. Inhibition of mitochondrial protein synthesis results in increased endothelial cell susceptibility to nitric oxide-induced apoptosis. Proc Natl Acad Sci USA 2002; 99: 6643-8.
40. Victor VM, Nuñez C, D'Ocon P, Taylor CT, Esplugues JV, Mon-cada S. Regulation of oxygen distribution in tissues by endothelial nitric oxide. Circ Res 2009; 104: 1178-83.
41. Hagen T, Taylor CT, Lam F, Moncada S. Redistribution of intra-cellular oxygen in hypoxia by nitric oxide: effect on HIF1 alpha. Science 2003; 302: 1975-8.
42. Devary Y, Rosette C, DiDonato JA, Karin M. NF-kappa B activation by ultraviolet light not dependent on a nuclear signal. Science 1993; 261: 1442-5.
43. Gloire G, Piette J. Redox regulation of nuclear post-translational modifications during NF-kappaB activation. Antioxid Redox Signal 2009; 11: 2209-22.
44. Federico A, Morgillo F, Tuccillo C, Ciardiello F, Loguercio C. Chronic inflammation and oxidative stress in human carcinogene-sis. Int J Cancer 2007; 121: 2381-2386.
45. Ohshima H, Tatemichi M, Sawa T. Chemical basis of inflammation-induced carcinogenesis. Arch Biochem Biophys 2003; 417: 3-11.
46. Cebioglu M, Schild HH, Golubnitschaja O. Diabetes mellitus as a risk factor for cancer: stress or viral etiology? Infect Disord Drug Targets 2008; 8: 76-87.
47. Kern PA, Ranganathan S, Li C, Wood L, Ranganathan G. Adipose tissue tumour necrosis factor and interleukin- 6 expression in human obesity and insulin resistance. Am J Physiol 2001; 280: 745-751.
48. Szlosarek P, Charles KA, Balkwill FR. Tumour necrosis factor-alpha as a tumour promoter. Eur J Cancer 2006; 42: 745-750.
49. Kabat A, Ponicke K, Salameh A, Mohr FW, Dhein S. Effect of a beta 2-adrenoceptor stimulation on hyperglycemia-induced endo-thelial dysfunction. J Pharmacol Exp Ther 2004; 308: 564-573.
50. Hipkiss AR. Does chronic glycolysis accelerate aging? Could this explain how dietary restriction works? Ann N Y Acad Sci 2006; 1067: 361-368.
51. Hernandez-Mijares A, Garcia K, Sola-Izquierdo E, et al. Testosterone levels in males with type 2 diabetes and their relationship with cardiovascular risk factors and cardiovascular disease. J Sex Med 2010; 7:1954-1964.
52. García Malpartida K, Mármol Lozano R, Jover Fernández A, et al. Relationship between erectile dysfunction and silent myocardial ischaemia in type 2 diabetic patients with no known macrovascular complications. J Sex Med, in press. 2011
53. Nishikawa T, Edelstein D, Du XL, et al. Normalizing mitochon-drial superoxide production blocks three pathways of hypergly-caemic damage. Nature 2000; 404: 787-790.
54. Turrens JF, Boveris A. Generation of superoxide anion by the NADH dehydrogenase of bovine heart mitochondria. Biochem J 1980; 191: 421-427.
55. Verkaart S, Koopman WJ, van Emst de Vries SE, et al. Superoxide production is inversely related to complex I activity in inherited complex I deficiency. Biochim Biophys Acta 2007; 1772: 373-381.
56. Rotig A, de Lonlay P, Chretien D, et al. Aconitase and mitochon-drial iron-sulphur protein deficiency in Friedreich ataxia. Nat Genet 1997; 17: 215-217.
57. Martin-Hernandez E, Garcia-Silva MT, Vara J, et al. Renal pathology in children with mitochondrial diseases. Pediatr Nephrol 2005; 20: 1299-1305.
58. Diomedi-Camassei F, Di Giandomenico S, Santorelli FM, et al. COQ2 nephropathy: a newly described inherited mitochondriopa-thy with primary renal involvement. J Am Soc Nephrol 2007; 18: 2773-2780.
59. Hausse AO, Aggoun Y, Bonnet D, et al. Idebenone and reduced cardiac hypertrophy in Friedreich's ataxia. Heart 2002; 87:346-349.
60. Green K, Brand MD, Murphy MP. Prevention of mitochondrial oxidative damage as a therapeutic strategy in diabetes. Diabetes 2004; 53: S110-S118.
61. Chacko BK, Reily C, Srivastava A, et al. Prevention of diabetic nephropathy in Ins2(+/)(AkitaJ) mice by the mitochondria-targeted therapy MitoQ. Biochem J 2010; 432: 9-19.
62. Krauss S, Zhang CY, Scorrano L, et al. Superoxide-mediated activation of uncoupling protein 2 causes pancreatic beta cell dysfunction. J Clin Invest 2003; 112: 1831-1842.
63. Sivitz WI, Yorek MA. Mitochondrial dysfunction in diabetes: from molecular mechanisms to functional significance and therapeutic opportunities. Antioxidant Redox Signaling 2010; 12:1-42.
64. Kelley DE, He J, Menshikova EV, Ritov VB. Dysfunction of mitochondria in human skeletal muscle in type 2 diabetes. Diabetes 2002; 51: 2944-2950.
65. Morino K, Petersen KF, Dufour S, et al. Reduced mitochondrial density and increased IRS-1 serine phosphorylation in muscle of insulinresistant offspring of type 2 diabetic parents. J Clin Invest 2005; 115: 3587-3593.
66. Chao TT, Ianuzzo CD, Armstrong RB, Albright JT, Anapolle SE. Ultrastructural alterations in skeletal muscle fibers of streptozoto-cin-diabetic rats. Cell Tissue Res 1976; 168: 239-246.
67. Marinari UM, Monacelli R, Cottalasso D, Novelli A. Effects of alloxan diabetes and insulin on morphology and certain functional activities of mitochondria of the rat liver and heart. Acta Diabetol Lat 1974; 11: 296-314.
68. Cester N, Rabini RA, Salvolini E, et al. Activation of endothelial cells during insulin-dependent diabetes mellitus: a biochemical and morphological study. Eur J Clin Invest 1996; 26: 569-573.
69. Bugger H, Boudina S, Hu XX, et al. Type 1 diabetic akita mouse hearts are insulin sensitive but manifest structurally abnormal mitochondria that remain coupled despite increased uncoupling protein 3. Diabetes 2008; 57: 2924-2932.
70. Boudina S, Sena S, Theobald H, et al. Mitochondrial energetics in the heart in obesity-related diabetes: direct evidence for increased uncoupled respiration and activation of uncoupling proteins. Diabetes 2007; 56: 2457-2466.
71. Li Z, Okamoto K, Hayashi Y, Sheng M. The importance of dendritic mitochondria in the morphogenesis and plasticity of spines and synapses. Cell 2004; 119: 873-887.
72. Civitarese AE and Ravussin E. Minireview: mitochondrial energetics and insulin resistance. Endocrinology 2008; 149: 950-954.
73. Bach D, Pich S, Soriano FX, et al. Mitofusin-2 determines mito-chondrial network architecture and mitochondrial metabolism: a novel regulatory mechanism altered in obesity. J Biol Chem 2003; 278: 17190-17197.
74. Walder K, Kerr-Bayles L, Civitarese A, et al. The mitochondrial rhomboid protease PSARL is a new candidate gene for type 2 diabetes. Diabetologia 2005; 48: 459-468.
75. Duncan JG, Fong JL, Medeiros DM, Finck BN, Kelly DP. Insulin-resistant heart exhibits a mitochondrial biogenic response driven by the peroxisome proliferator activated receptor-alpha-PGC-1alpha gene regulatory pathway. Circulation 2007; 115: 909-917.
76. Wu Z, Puigserver P, Andersson U, et al. Mechanisms controlling mitochondrial biogenesis and respiration through the thermogenic coactivator PGC-1. Cell 1999; 98: 115-124.
77. Feige JN, Auwerx J. Transcriptional coregulators in the control of energy homeostasis. Trends Cell Biol 2007; 17: 292-301.
78. Brown GC, Borutaite V. Nitric oxide, mitochondria, and cell death. IUBMB Life 2001; 52: 189-195.
79. Canto C, Auwerx J. PGC-1alpha, SIRT1 and AMPK, an energy sensing network that controls energy expenditure. Curr Opin Lipi-dol 2009; 20: 98-105.
80. Reznick RM, Shulman GI. The role of AMP-activated protein kinase in mitochondrial biogenesis. J Physiol 2006; 574: 33-39.
81. Rodgers JT, Lerin C, Haas W, Gygi SP, Spiegelman BM, and Puig-server P. Nutrient control of glucose homeostasis through a complex of PGC-1alpha and SIRT1. Nature 2005; 434: 113-118.
82. Nisoli E, Carruba MO. Nitric oxide and mitochondrial biogenesis. J Cell Sci 2006; 119: 2855-2862.
83. Nisoli E, Clementi E, Paolucci C, et al. Mitochondrial biogenesis in mammals: the role of endogenous nitric oxide. Science 2003; 299: 896-899.
84. Koves TR, Li P, An J, et al. Peroxisome proliferator-activated receptor-gamma co-activator 1alpha-mediated metabolic remodeling of skeletal myocytes mimics exercise training and reverses lipid-induced mitochondrial inefficiency. J Biol Chem 2005; 280: 33588-33598.
85. Benton CR, Nickerson JG, Lally J, et al. Modest PGC-1alpha over-expression in muscle in vivo is sufficient to increase insulin sensitivity and palmitate oxidation in infsarcolemmal, not intermyofi-brillar, mitochondria. J Biol Chem 2008; 283: 4228-4240.
86. Arany Z, He H, Lin J, et al. Transcriptional coactivator PGC-1 alpha controls the energy state and contractile function of cardiac muscle. Cell Metab 2005; 1: 259-271.
87. Duncan JG, Fong JL, Medeiros DM, Finck BN, Kelly DP. Insulin-resistant heart exhibits a mitochondrial biogenic response driven by the peroxisome proliferatoractivated receptor-alpha-PGC-1alpha gene regulatory pathway. Circulation 2007; 115: 909-917.
88. Lin J, Wu H, Tarr PT, et al. Transcriptional co-activator PGC-1 alpha drives the formation of slow-twitch muscle fibres. Nature 2002; 418: 797-801.
89. Mensink M, Hesselink MK, Russell AP, Schaart G, Sels JP, Schrauwen P. Improved skeletal muscle oxidative enzyme activity and restoration of PGC-1 alpha and PPAR beta-delta gene expression upon rosiglitazone treatment in obese patients with type 2 diabetes mellitus. Int J Obes 2007; (Lond) 31: 1302-1310.
90. Mootha VK, Lindgren CM, Eriksson KF, et al. PGC-1alpha-responsive genes involved in oxidative phosphorylation are coordi-nately downregulated in human diabetes. Nat Genet 2003; 34: 267-273.
91. Patti ME, Butte AJ, Crunkhorn S, et al. Coordinated reduction of genes of oxidative metabolism in humans with insulin resistance and diabetes: potential role of PGC 1 and NRF1. Proc Natl Acad Sci U S A 2003; 100: 8466-8471.
92. Handschin C, Choi CS, Chin S, et al. Abnormal glucose homeostasis in skeletal muscle-specific PGC-1alpha knockout mice reveals skeletal muscle-pancreatic beta cell crosstalk. J Clin Invest 2007;117: 3463-3474.
93. Leone TC, Lehman JJ, Finck BN, et al. PGC-1alpha deficiency causes multi-system energy metabolic derangements: muscle dysfunction, abnormal weight control and hepatic steatosis. PLoS Biol 2005; 3: e101.
94. Echtay KS, Murphy MP, Smith RA, Talbot DA, Brand MD. Superoxide activates mitochondrial uncoupling protein 2 from the matrix side: studies using targeted antioxidants. J Biol Chem 2002; 277: 47129-47135.
95. Matveyenko AV, Gurlo T, Davel M, Beutler AE, Butler PC. Successful versus failed adaptation to high-fat diet-induced insulin resistance. Diabetes 2009; 58: 906-916.
96. Winslow AR, Rubinsztein DC. Autophagy in neurodegeneration and development. Biochim Biophys Acta 2008; 1782: 723-729.
97. Ebato C, Uchida T, Arakawa M et al. Autophagy is important in islet homeostasis and compensatory increase of Beta cell mass in response to high-fat diet. Cell Metab 2008; 8: 325-332.
98. Jung HS, Chung KW, Kim JW et al. Loss of autophagy diminishes pancreatic β-cell mass and function with resultant hyperglycemia. Cell Metab 2008; 8: 318-324.
99. Marsh BJ, Soden C,Alarcon C et al. Regulated autophagy controls hormone content in secretory-deficient pancreatic endocrine beta-cells. Mol Endocrinol 2007; 21: 2255-2269.
100. Kaniuk NA, Kiraly M, Bates H et al. Ubiquitinated-protein aggregates form in pancreatic beta-cells during diabetes-induced oxidative stress and are regulated by autophagy. Diabetes 2007; 56: 930-939.
101. Um SH, Frigerio F, Watanabe M et al. Absence of S6K1 protects against age- and diet-induced obesity while enhancing insulin sensitivity. Nature 2004; 431: 200-205.
102. Choi SE, Lee SM, Lee YJ et al. Protective role of autophagy in palmitateinduced INS-1 beta cell death. Endocrinology 2008; 150: 126-134.
103. Ogata M, Hino SI, Saito A, et al. Autophagy is activated for cell survival after endoplasmic reticulum stress. Mol Cell Biol 2006; 26: 9220-9231.
104. Gozuacik D, Bialik S, Raveh T et al. DAP-kinase is a mediator of endoplasmic reticulum stress-induced caspase activation and autophagic cell death. Cell Death Differ 2008; 15: 1875-1886.
105. Levine B, Yuan J. Autophagy in cell death: an innocent convict? J Clin Invest 2005; 115: 2679-2688.
106. Kim EH, Sohn S, Kwon HJ et al. Sodium selenite induces superox-idemediated mitochondrial damage and infsequent autophagic cell death in malignant glioma cells. Cancer Res 2007; 67: 6314-6324.
107. Yousefi S, Perozzo R, Schmid I et al. Calpain-mediated cleavage of Atg5 switches autophagy to apoptosis. Nat Cell Biol 2006; 8: 1124-1132.
108. Yu L, Wan F, Dutta S et al. Autophagic programmed cell death by selective catalase degradation. Proc Natl Acad Sci U S A 2006; 103: 4952-4957.
109. Pyo JO, Jang MH, Kwon YK et al. Essential roles of Atg5 and FADD in autophagic cell death: dissection of autophagic cell death into vacuole formation and cell death. J Biol Chem 2007; 280: 20722-20729.
110. Hara T, Nakamura K, Matsui M et al. Suppression of basal autophagy in neural cells causes neurodegenerative disease in mice. Nature 2006; 441: 885-889.
111. Komatsu M, Waguri S, Chiba T et al. Loss of autophagy in the central nervous system causes neudodegeneration in mice. Nature 2006; 441: 880-884.
112. Bernales S, Schuck S, Walter P. ER-phagy: selective autophagy of the endoplasmic reticulum. Autophagy 2007; 3: 285-287.
113. Rodriguez-Enriquez S, Kim I, Currin RT, Lemasters JJ. Tracker dyes to probe mitochondrial autophagy (mitophagy) in rat hepato-cytes. Autophagy 2006; 2: 39-46.
114. Maechler P, Wollheim CB. Mitochondrial glutamate acts as a Messenger in glucose-induced insulin exocytosis. Nature 1999; 402: 685-689.
115. Laybutt DR, Preston AM, Akerfeldt MC et al. Endoplasmic reticulum stress contributes to beta cell apoptosis in type 2 diabetes. Dia-betologia 2007; 50: 752-763.
116. Twig G, Elorza A, Molina AJ et al. Fission and selective fusion govern mitochondrial segregation and elimination by autophagy. EMBO J 2008; 27: 433-446.
117. Kanki T, Wang K, Cao Y, Baba M, Klionsky DJ. Atg32 is a mitochondrial protein that confers selectivity during mitophagy. Dev Cell 2009; 17: 98-109.
118. Novak I, Kirkin V, McEwan DG et al. Nix is a selective autophagy receptor for mitochondrial clearance. EMBO Rep 2010; 11: 45-51.
119. Okamoto K, Kondo-Okamoto N, Ohsumi Y. Mitochondria-anchored receptor Atg32 mediates degradation of mitochondria via selective autophagy. Dev Cell 2009; 17: 87-97.
120. Ravikumar B, Berger Z, Vacher C, O'Kane CJ, Rubinsztein DC. Rapamycin pre-treatment protects against apoptosis. Hum Mol Genet 2006; 15: 1209-1216.
121. Nakai A, Yamaguchi O, Takeda T et al. The role of autophagy in cardiomyocytes in the basal state and in response to hemodynamic stress. Nat Med 2007; 13: 619-624.
122. Harding HP, Zeng H, Zhang Y et al. Diabetes mellitus and exocrine pancreatic dysfunction in perk-/- mice reveals a role for translational control in secretory cell survival. Mol Cell 2001; 7: 1153-1163.
123. Wu J, Kaufman RJ. From acute ER stress to physiological roles of the unfolded protein response. Cell Death Differ 2006; 13: 374-384.
124. Liang J, Shao SH, Xu ZX et al. The energy sensing LKB1-AMPK pathway regulates p27(kip1) phosphorylation mediating the decision to enter autophagy or apoptosis. Nat Cell Biol 2007; 9: 218-224.
125. Saitoh T, Fujita N, Jang MH et al. Loss of the autophagy protein Atg16L1 enhances endotoxin-induced IL-1beta production. Nature 2008; 456: 264-269.
126. Tal MC, Sasai M, Lee HK et al. Absence of autophagy results in reactive oxygen species-dependent amplification of RLR signaling. Proc Natl Acad Sci U S A 2009; 106: 2770-2775.
127. Pandey UB, Nie Z, Batlevi Y et al. HDAC6 rescues neurodegen-eration and provides an essential link between autophagy and the UPS. Nature 2007; 447: 859-863.
128. Rubinsztein DC. The roles of intracellular protein-degradation pathways in neurodegeneration. Nature 2006; 443: 780-786.
129. Arrasate M, Mitra S, Schweitzer ES, Segal MR, Finkbeiner S. Inclusion body formation reduces levels of mutant huntingtin and the risk of neuronal death. Nature 2004; 431: 805-810.
130. Janson J, Ashley RH, Harrison D, McIntyre S, Butler PC. The mechanism of islet amyloid polypeptide toxicity ismembrane disruption by intermediatesized toxic amyloid particles. Diabetes 1999; 48: 491-498.
131. Komatsu M, Waguri S, Koike M et al. Homeostatic levels of p62 control cytoplasmic inclusion body formation in autophagy-deficient mice. Cell 2007; 131: 1149-1163.
132. Moscat J, Diaz-Meco MT, Wooten MW. Signal integration and diversification through the p62 scaffold protein. Trends Biochem Sci 2007; 32: 95-100.
133. Zatloukal K, Stumptner C, Fuchsbichler A, et al. P62 Is a common component of cytoplasmic inclusions in protein aggregation diseases. Am J Pathol 2002; 160: 255-263.
134. Ichimura Y, Kumanomidou T, Sou YS et al. Structural basis for sorting mechanism of p62 in selective autophagy. J Biol Chem 2008; 283: 22847-22857.
135. Hiruma Y, Kurihara N, Infler MA et al. A SQSTM1/p62 mutation linked to Paget's disease increases the osteoclastogenic potential of the bone microenvironment. Hum Mol Genet 2008; 17: 3708-3719.
136. Rodriguez A, Duran A, Selloum M et al. Mature-onset obesity and insulin resistance in mice deficient in the signaling adapter p62. Cell Metab 2006; 3: 211-222.
137. Komatsu M, Kurokawa H, Waguri S, et al. The selective autophagy infstrate p62 activates the stress responsive transcription factor Nrf2 through inactivation of Keap1. Nat Cell Biol 2010; 12: 213-223.
138. Menendez-Benito V, Verhoef LGGC, Masucci MG, Dantuma NP. Endoplasmic reticulum stress compromises the ubiquitin- proteasome system. Hum Mol Genet 2005; 14: 2787-2799.
139. Ohsaki Y, Cheng J, Suzuki M, Fujita A, Fujimoto T. Lipid droplets are arrested in the ER membrane by tight binding of lipidated apol-ipoprotein B-100. J Cell Sci 2008; 121: 2415-2422.
140. Ozcan U, Cao Q, Yilmaz E et al. Endoplasmic reticulum stress links obesity, insulin action, and type 2 diabetes. Science 2004; 306: 457-461.
141. Rutkowski DT, Wu J, Back SH et al. UPR pathways combine to prevent hepatic steatosis caused by ER stress-mediated suppression of transcriptional master regulators. Dev Cell 2008; 15: 829-840.
142. Singh R, Kaushik S, Wang Y et al. Autophagy regulates lipid metabolism. Nature 2009; 458: 1131-1135.
143. Shibata M, Yoshimura K, Furuya N et al. The MAP1-LC3 conjugation system is involved in lipid droplet formation. Biochem Bio-phys Res Comm 2009; 382: 419-423.
144. Ohsaki Y, Cheng J, Fujita A, Tokumoto T, Fujimoto T. Cytoplas-mic lipid droplets are sites of convergence of proteasomal and autophagic degradation of apolipoprotein B. Mol Biol Cell 2006; 17: 2674-2683.
145. Singh R, Xiang Y, Wang Y et al. Autophagy regulates adipose mass and differentiation in mice. J Clin Invest 2009; 119: 3329-3339.
146. Zhang Y, Goldman S, Baerga R et al. Adipose-specific deletion of autophagy-related gene 7 (atg7) in mice reveals a role in adipo-genesis. Proc Natl Acad Sci U S A 2009; 106: 19860-19865.
147. Houstis N, Rosen ED, Lander ES. Reactive oxygen species have a causal role in multiple forms of insulin resistance. Nature 2006; 440: 944-948.
148. Petersen KF, Dufour S, Befroy D, Garcia R, Shulman GI. Impaired mitochondrial activity in the insulin-resistant offspring of patients with type 2 diabetes. N Engl J Med 2004; 350: 664-671.
149. Ozcan U, Yilmaz E, Ozcan L et al. Chemical chaperones reduce ER stress and restore glucose homeostasis in a mouse model of type 2 diabetes. Science 2006; 313: 1137-1140.
150. Ceriello A, Morocutti A, Mercuri F, et al. Defective intracellular antioxidant enzyme production in type 1 diabetic patients with nephropathy. Diabetes 2000; 49: 2170-2177.
151. DeRubertis FR, Craven PA, Melhem MF. Acceleration of diabetic renal injury in the superoxide dismutase knockout mouse: effects of tempol. Metabolism 2007; 56: 1256-1264.
152. Hinerfeld D, Traini MD, Weinberger RP, et al. Endogenous mito-chondrial oxidative stress: neurodegeneration, proteomic analysis, specific respiratory chain defects, and efficacious antioxidant therapy in superoxide dismutase 2 null mice. J Neurochem 2004; 88: 657-667.
153. Asaba K, Tojo A, Onozato ML, Goto A, Fujita T. Double-edged action of SOD mimetic in diabetic nephropathy. J Cardiovasc Pharmacol 2007; 49: 13-19.
154. Mollsten A, Marklund SL, Wessman M, et al. A functional polymorphism in the manganese superoxide dismutase gene and diabetic nephropathy. Diabetes 2007; 56: 265-269.
155. de Haan JB, Stefanovic N, Nikolic-Paterson D, et al. Kidney expression of glutathione peroxidase-1 is not protective against strep-tozotocin-induced diabetic nephropathy. Am J Physiol Renal Physiol 2005; 289: F544-F551.
156. Brezniceanu ML, Liu F, Wei CC, et al. Catalase overexpression attenuates angiotensinogen expression and apoptosis in diabetic mice. Kidney Int 2007; 71: 912-923.
157. dos Santos KG, Canani LH, Gross JL, Tschiedel B, Souto KE, Roisenberg I. The catalase -262C/T promoter polymorphism and diabetes complications in Caucasians with type 2 diabetes. Dis Markers 2006; 22: 355-359.
158. Yorek MA. The role of oxidative stress in diabetic vascular and neural disease. Free Radic Res 2003; 37: 471480, 2003.
159. Yusuf S, Dagenais G, Pogue J, Bosch J, Sleight P. Vitamin E supplementation and cardiovascular events in high-risk patients: the Heart Outcomes Prevention Evaluation Study investigators. N Engl J Med 2000; 342: 154-160.
160. Modi K, Santani DD, Goyal RK, Bhatt PA. Effect of coenzyme Q10 on catalase activity and other antioxidant parameters in streptozotocin-induced diabetic rats. Biol Trace Elem Res 2006; 109: 25-34.
161. Rauscher FM, Sanders RA, Watkins JB. Effects of coenzyme Q10 treatment on antioxidant pathways in normal and streptozoto-cin-induced diabetic rats. J Biochem Mol Toxicol 2001;15: 41-46.
162. Andersen CB, Henriksen JE, Hother-Nielsen O, Vaag A, Mort-ensen SA, Beck-Nielsen H. The effect of coenzyme Q10 on blood glucose and insulin requirement in patients with insulin dependent diabetes mellitus. Mol Aspects Med 1997; 18(suppl): S307-S309.
163. Henriksen JE, Andersen CB, Hother-Nielsen O, Vaag A, Mort-ensen SA, Beck-Nielsen H. Impact of ubiquinone (coenzyme Q10) treatment on glycaemic control, insulin requirement and well-being in patients with type 1 diabetes mellitus. Diabetes Med 1999; 16: 312-318.
164. Modi K, Santani DD, Goyal RK, Bhatt PA. Effect of coenzyme Q10 on catalase activity and other antioxidant parameters in strep-tozotocin-induced diabetic rats. Biol Trace Elem Res 2006;109: 25-34.
165. Suzuki S, Hinokio Y, Ohtomo M, et al. The effects of coenzyme Q10 treatment on maternally inherited diabetes mellitus and deafness, and mitochondrial DNA 3243 (A to G) mutation. Diabetolo-gia 1998; 41: 584-588.
166. Kunitomo M, Yamaguchi Y, Kagota S, Otinfo K. Beneficial effect of coenzyme Q10 on increased oxidative and nitrative stress and inflammation and individual metabolic components developing in a rat model of metabolic syndrome. J Pharmacol Sci 2008; 107: 128-137.
167. Rauscher FM, Sanders RA, and Watkins JB 3rd. Effects of coen-zyme Q10 treatment on antioxidant pathways in normal and strep-tozotocin-induced diabetic rats. J Biochem Mol Toxicol 2001;15: 41-46.
168. Murad LB, Guimaraes MR, Vianna LM. Effects of decylubiqui-none (coenzyme Q10 analog) supplementation on SHRSP. Biofac-tors 2007;30: 13-18.
169. Moreira PI, Santos MS, Sena C, Nunes E, Seica R, Oliveira CR. CoQ10 therapy attenuates amyloid beta-peptide toxicity in brain mitochondria isolated from aged diabetic rats. Exp Neurol 2005; 196: 112-119.
170. Haas RH. The evidence basis for coenzyme Q therapy in oxidative phosphorylation disease. Mitochondrion 2007; 7(suppl): S136-S145.
171. Ernster L, Forsmark P, and Nordenbrand K. The mode of action of lipid-soluble antioxidants in biological membranes: relationship between the effects of ubiquinol and vitamin E as inhibitors of lipid peroxidation in infmitochondrial particles. Biofactors 1992;3: 241-248.
172. Maguire JJ, Wilson DS, and Packer L. Mitochondrial electron transport-linked tocopheroxyl radical reduction. J Biol Chem 1989; 264: 21462-21465.
173. Fink BD, O'Malley Y, Dake BL, Ross NC, Prisinzano TE, Sivitz WI. Mitochondrial targeted coenzyme Q, superoxide, and fuel selectivity in endothelial cells. PLoS ONE 2009;4: e4250.
174. O'Malley Y, Fink BD, Ross NC, Prisinzano TE, Sivitz WI. Reactive oxygen and targeted antioxidant administration in endothelial cell mitochondria. J Biol Chem 2006; 281: 39766-39775.
175. Thomas SM, Gebicki JM, Dean RT. Radical initiated alpha-tocopherol depletion and lipid peroxidation in mitochondrial membranes. Biochim Biophys Acta 1989; 1002: 189-197.
176. Lonn E, Bosch J, Yusuf S, et al. Effects of long-term vitamin E supplementation on cardiovascular events and cancer: a randomized controlled trial. JAMA 2005; 293: 1338-1347.
177. Lonn E, Yusuf S, Dzavik V, et al. Effects of ramipril and vitamin E on atherosclerosis: the study to evaluate carotid ultrasound changes in patients treated with ramipril and vitamin E (SECURE). Circulation 2001; 103: 919-925.
178. Beckman JA, Goldfine AB, Gordon MB, et al. Oral antioxidant therapy improves endothelial function in Type 1 but not Type 2 diabetes mellitus. Am J Physiol Heart Circ Physiol 2003; 285: H2392-H2398.
179. Economides PA, Khaodhiar L, Caselli A, et al. The effect of vitamin E on endothelial function of micro- and macrocirculation and left ventricular function in type 1 and type 2 diabetic patients. Diabetes 2005; 54: 204-211.
180. May JM, Qu ZC, Li X. Ascorbic acid blunts oxidant stress due to menadione in endothelial cells. Arch Biochem Biophys 2003; 411: 136-144.
181. Smith AR, Visioli F, Hagen TM. Vitamin C matters: increased oxidative stress in cultured human aortic endothelial cells without supplemental ascorbic acid. FASEB J 2002; 16: 125-144.
182. American Diabetes Association. Standards of medical care in diabetes. Diabetes Care 2009; 32(suppl 1): S13-S61.
183. Yorek MA, Coppey LJ, Gellett JS, Davidson EP, Lund DD. Effect of fidarestat and alpha-lipoic acid on diabetesinduced epineurial ar-teriole vascular dysfunction. Exp Diabesity Res 2004;5: 123-135.
184. Obrosova IG, Stevens MJ, Lang HJ. Diabetes-induced changes in retinal NAD-redox status: pharmacological modulation and implications for pathogenesis of diabetic retinopathy. Pharmacology 2001; 62: 172-180.
185. Dincer Y, Telci A, Kayali R, Yilmaz IA, Cakatay U, Akcay T. Effect of alpha-lipoic acid on lipid peroxidation and anti-oxidant enzyme activities in diabetic rats. Clin Exp Pharmacol Physiol 2002; 29: 281-284.
186. Yi X, Maeda N. Alpha-Lipoic acid prevents the increase in atherosclerosis induced by diabetes in apolipoprotein Edeficient mice fed high-fat low-cholesterol diet. Diabetes 2006; 55: 2238-2244.
187. Kowluru RA, Odenbach S. Effect of long-term administration of alpha-lipoic acid on retinal capillary cell death and the development of retinopathy in diabetic rats. Diabetes 2004; 53: 3233-3238.
188. Ziegler D, Hanefeld M, Ruhnau KJ, et al. Treatment of symptomatic diabetic peripheral neuropathy with the anti-oxidant al-phalipoic acid: a 3-week multicentre randomized controlled trial (ALADIN Study). Diabetologia 1995; 38: 1425-1433.
189. Ziegler D, Ametov A, Barinov A, et al. Oral treatment with alpha-lipoic acid improves symptomatic diabetic polyneuropathy: the SYDNEY 2 trial. Diabetes Care 2006; 29: 2365-2370.
190. Cotgreave IA. N-acetylcysteine: pharmacological considerations and experimental and clinical applications. Adv Pharmacol 1997; 38: 205-227.
191. Mehta K, Van Thiel DH, Shah N, Mobarhan S. Nonalcoholic fatty liver disease: pathogenesis and the role of antioxidants. Nutr Rev 2002; 60: 289-293.
192. Jo SH, Koo BK, Park JS, et al. N-acetylcysteine versus ascorbic acid for preventing contrast-induced nephropathy in patients with renal insufficiency undergoing coronary angiography NASPI study: a prospective randomized controlled trial. Am Heart J 2009; 157: 576-583.
193. Li M, Peterson S, Husney D, et al. Interdiction of the diabetic state in NOD mice by sustained induction of heme oxygenase: possible role of carbon monoxide and bilirubin. Antioxid Redox Signal 2007; 9: 855-863.
194. Li M, Kim DH, Tsenovoy PL, Peterson SJ, et al. Treatment of obese diabetic mice with a heme oxygenase inducer reduces visceral and infcutaneous adiposity, increases adiponectin levels, and improves insulin sensitivity and glucose tolerance. Diabetes 2008; 57: 1526-1535.
195. Kelso GF, Porteous CM, Coulter CV, et al. Selective targeting of a redox-active ubiquinone to mitochondria within cells: antioxidant and antiapoptotic properties. J Biol Chem 2001; 276: 4588-4596.
196. Rocha M, Apostolova N, Hernandez-Mijares A, Herance R, Victor VM. Oxidative stress and endothelial dysfunction in cardiovascular disease: mitochondria-targeted therapeutics. Curr Med Chem 2010;17:3827-41.
197. González-Rubio S, Hidalgo AB, Ferrín G, et al. Mitochondrial-driven ubiquinone enhances extracellular calcium-dependent nitric oxide production and reduces glycochenodeoxycholic acid-induced cell death in hepatocytes. Chem Res Toxicol 2009;22:1984-1991.
198. Murphy MP. Selective targeting of bioactive compounds to mitochondria. Trends Biotechnol 1997; 15: 326-330.
199. James AM, Smith RA, Murphy MP. Antioxidant and prooxidant properties of mitochondrial coenzyme Q. Arch Biochem Biophys 2004; 423: 47-56.
200. Adlam VJ, Harrison JC, Porteous CM, et al. Targeting an antioxi-dant to mitochondria decreases cardiac ischemia-reperfusion injury. FASEB J 2005; 19: 1088-1095.
201. Jauslin ML, Meier T, Smith RA, Murphy MP. Mitochondria-targeted antioxidants protect Friedreich ataxia fibroblasts from endogenous oxidative stress more effectively than untargeted antioxi-dants. FASEB J 2003; 17: 1972-1974.
202. Saretzki G, Murphy MP, von Zglinicki T. MitoQ counteracts te-lomere shortening and elongates lifespan of fibroblasts under mild oxidative stress. Aging Cell 2003; 2: 141-143.
203. Dhanasekaran A, Kotamraju S, Kalivendi SV, et al. Supplementation of endothelial cells with mitochondriatargeted antioxidants inhibit peroxide-induced mitochondrial iron uptake, oxidative damage, and apoptosis. J Biol Chem 2004; 279: 37575-37587.
204. Schafer M, Schafer C, Ewald N, Piper HM, Noll T. Role of redox signaling in the autonomous proliferative response of endothelial cells to hypoxia. Circ Res 2003; 92: 1010-1015.
205. Doughan AK Dikalov SI. Mitochondrial redox cycling of mitoqui-none leads to superoxide production and cellular apoptosis. Anti-oxid Redox Signal 2007; 9: 1825-1836.
206. Drose S, Brandt U. The mechanism of mitochondrial superoxide production by the cytochrome bc1 complex. J Biol Chem 2008; 283: 21649-21654.
207. Rocha M, Hernandez-Mijares A, Garcia-Malpartida K, Bañuls C, Bellod L, Victor VM. Mitochondria-targeted antioxidant peptides. Curr Pharm Des. 2010;16:3124-31.
208. Szeto HH. Development of mitochondria-targeted aromatic-cationic peptides for neurodegenerative diseases. Ann N Y Acad Sci 2008; 1147: 112-121.
209. Zhao K, Zhao GM, Wu D, et al. Cell-permeable peptide antioxi-dants targeted to inner mitochondrial membrane inhibit mitochon-drial swelling, oxidative cell death, and reperfusion injury. J Biol Chem 2004; 279: 34682-34690.
210. Petri S, Kiaei M, Damiano M, et al. Cell-permeable peptide anti-oxidants as a novel therapeutic approach in a mouse model of amyotrophic lateral sclerosis. J Neurochem 2006; 98: 1141-1148.
211. Thomas DA, Stauffer C, Zhao K, et al. Mitochondrial targeting with antioxidant peptide SS-31 prevents mitochondrial depolarization, reduces islet cell apoptosis, increases islet cell yield, and improves posttransplantation function. J Am, Soc Nephrol 2007; 18: 213-222.
212. Anderson EJ, Lustig ME, Boyle KE, et al. Mitochondrial H2O2 emission and cellular redox state link excess fat intake to insulin resistance in both rodents and humans. J Clin Invest 2009;119:573-81.
213. Zhao K, Luo G, Zhao GM, Schiller PW, Szeto HH. Transcellular transport of a highly polar 3b net charge opioid tetrapeptide. J Pharmacol Exp Ther 2003; 304: 425-432.
214. Thiemermann C. Membrane-permeable radical scavengers (tempol) for shock, ischemia-reperfusion injury, and inflammation. Crit Care Med 2003; 31: S76-S84.
215. Tang C, Han P, Oprescu AI, Lee SC, et al. Evidence for a role of superoxide generation in glucose-induced beta-cell dysfunction in vivo. Diabetes 2007; 56: 2722-2731.
216. Oprescu AI, Bikopoulos G, Naassan A, et al. Free fatty acid-induced reduction in glucose-stimulated insulin secretion: evidence for a role of oxidative stress in vitro and in vivo. Diabetes 2007; 56: 2927-2937.
217. Asaba K, Tojo A, Onozato ML, Goto A, Fujita T. Double-edged action of SOD mimetic in diabetic nephropathy. J Cardiovasc Pharmacol 2007; 49: 13-19.
218. Nassar T, Kadery B, Lotan C, Da'as N, Kleinman Y, Haj-Yehia A. Effects of the superoxide dismutasemimetic compound tempol on endothelial dysfunction in streptozotocin-induced diabetic rats. Eur J Pharmacol 2002; 436: 111-118.